Navigation Links
NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., a privately held specialty pharmaceutical company, today announced positive results from an initial Phase I study of NP101 SmartRelief, a novel treatment for acute migraine being developed by NuPathe.

NP101 combines NuPathe's SmartRelief(TM) proprietary iontophoretic transdermal technology with sumatriptan, the most widely prescribed treatment for acute migraine in the United States. Sumatriptan is also the active ingredient in IMITREX(R), which is also indicated for the treatment of acute migraine.

The study was a randomized, single-center, single-dose, six-period pilot study to evaluate four SmartRelief(TM) prototypes. The study compared sumatriptan pharmacokinetics and safety following administration of NP101 SmartRelief(TM) prototype patches, IMITREX 50 mg tablets, and IMITREX 6 mg subcutaneous injection. Results of the Phase I study were presented today in a poster presentation at the American Headache Society meeting in Chicago.

In the study, NP101 maintained continual therapeutic dosing levels of sumatriptan an average of four times longer than treatment with the 6 mg injection of IMITREX and up to twice as long as treatment with the 50 mg tablet of IMITREX. NP101 was also generally well tolerated.

"These results demonstrate that NuPathe's transdermal technology can deliver therapeutic drug levels quickly and then maintain those levels over a sustained period of time, which may significantly improve consistency of response and decrease frequency of recurrent migraines in patients," said Steven J. Siegel, MD, PhD, assistant professor, University of Pennsylvania, who presented the results in Chicago. "This controlled delivery option could represent an important alternative for patients who experience gastrointestinal disorders such as nausea and vomiting during their migraine attack."

According to Jane Hollingsworth , CEO of NuPathe, "Patients need better options for treatment of acute migraine attacks. Triptans, which are considered the gold standard in treatment today, are proven to be efficacious, but they often result in inconsistent response, nausea, and recurrent headaches. Through NuPathe's patented transdermal delivery system, NP101 is designed to deliver sumatriptan in a consistent and sustained manner through a patch, significantly reducing the risk of GI problems."

About Migraine

Migraine is a widespread, chronic condition that affects approximately 25 million Americans. The primary symptoms include intense and disabling headache, acute sensitivity to light and sound, nausea, and aura. Some experts estimate that the loss of productivity associated with migraine costs the US economy between $13 and $17 billion each year. (1)

About Iontophoresis

Iontophoresis is a non-invasive process for actively transporting drugs through the skin and into underlying tissue. During iontophoresis charged molecules are propelled through the skin using bi-polar electrical fields. Iontophoretic products have been approved for multiple medical and therapeutic uses.

About NuPathe

NuPathe specializes in the development of therapeutics for the treatment of neurological and psychiatric disorders including migraine, Parkinson's disease and schizophrenia. NuPathe's lead product, NP101, uses SmartRelief(TM), the company's novel, transdermal patch technology, to deliver sumatriptan, a widely-used therapy for the treatment of acute migraine. Pending regulatory review and approval, NP101 would be the first ever migraine treatment based on a transdermal patch delivery. Phase I clinical results for NP101 have thus far demonstrated rapid delivery of migraine medication and improved pharmacokinetics compared to current standard of care. For additional information, visit

(1) Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of m igraine in the United States: disability and economic costs. Arch Intern Med 1999; 159(8):813-818.


NuPathe Inc.
Berry & Company

Kim Angelastro, 212-253-8881


Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Yesterday Congresswoman Renee Ellmers ... manufacturing site located in Holly Springs, NC ... produced Flucelvax ® (Influenza Vaccine) using cell-culture technology, a ... start-up and is not reliant on chicken eggs. 1,2 ... influenza vaccines business of Novartis AG in the US, ...
(Date:10/12/2015)... -- Given the intricacy of the anatomy and ... an ophthalmic drug effectively to a specific ocular site. Several ... delivery. These include dilution of a drug by tears, clearance ... drug permeation issues with respect to the cornea, sclera and ... is lost due to the aforementioned barriers. --> ...
(Date:10/12/2015)... and CRANBURY, N.J. , Oct. ... LLP announces that a securities fraud class ... for the District of New Jersey.  The complaint alleges ... FOLD) violated the Securities Exchange Act of 1934 between ... materially false and misleading statements about Amicus Therapeutics, business ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... NavaFit Inc. today announced the launch of its NavaFit app ... in local fitness & sporting events, and stay motivated. Users can download ... drive us to get more serious about fitness and wellness, individuals are constantly looking ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will ... Ranch and will unite customers, partners, WennSoft team members and sponsors to facilitate ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama Partnership for ... their regional telehealth summits for Fall 2015. , Each of the three ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, Bryce ... on August 26. Berry, who owns and operates Gold's Gym Cheyenne in ... Gold’s Gyms in the United States. A brand leader in global fitness, Gold’s Gyms ...
(Date:10/13/2015)... ... October 13, 2015 , ... With Fall weather approaching and ... for this month’s Facebook Hair Styler Contest. , Enter to win! , How to ... What Is Your Favorite Hair Style? , 3. Follow us on Instagram @thebeautyplace ...
Breaking Medicine News(10 mins):